Probability of prostate cancer at various levels of per cent free prostate specific antigen in Japanese men with total PSA of 4.1-10.0 ng/ml

Prostate Cancer and Prostatic Diseases

Volumn 5, Issue 2, 2002, Pages 115-118

  Egawa, S ^a   Suyama, K ^a   Takashima, R ^a   Kuwao, S ^a   Baba, S ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

per cent free prostate specific antigen; Prostate cancer; Racial difference; Total prostate specific antigen; Ultrasound guided biopsy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; ECHOGRAPHY; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; PALPATION; PRIORITY JOURNAL; PROBABILITY; PROSTATE BIOPSY; PROSTATE CANCER; RACE DIFFERENCE; ROC CURVE; TRANSURETHRAL RESECTION; AGED; BIOPSY; ETHNOLOGY; PATHOLOGY; PROSTATE TUMOR; REFERENCE VALUE; RISK FACTOR;

AGED; BIOPSY; HUMAN; JAPAN; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REFERENCE VALUES; RISK FACTORS; SUPPORT, NON-U.S. GOV'T; HUMANS;

EID: 0035996410     PISSN: 13657852     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500562     Document Type: Article

References (17)

1. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease. A prospective multicenter clinical trial
2. Free to total prostate-specific antigen (PSA) ratio is superior to total-PSA in differentiating benign prostate hypertrophy from prostate cancer
3. The ratio of free to total serum prostate specific antigen and its use in differential diagnosis of prostate carcinoma in Japan
4. Free to total prostate-specific antigen (PSA) ratio improves the discrimination between prostate cancer and benign prostatic hyperplasia (BPH) in the diagnostic gray zone of 1.8 to 10 ng/ml total PSA
5. A study on pretreatment nomogram to predict pathological stage and biochemical recurrence after radical prostatectomy for clinically resectable prostate cancer in Japanese men
6. Probability of prostate cancer detection based on results of a multicenter study using the AxSYM free PSA and total PSA assays
7. An algorithm combining age, total prostate-specific antigen (PSA), and percent free PSA to predict prostate cancer: Results on 4298 cases
8. Free/total PSA ratio improves differentiation of benign and malignant disease of the prostate: Critical analysis of two different test populations
9. Development of the Abbott AxSYM free PSA assay: Performance characteristics and preliminary clinical evaluation
10. Prospective evaluation of prostate cancer detection by prostate specific antigen-related cancer detection by prostate specific antigen-related parameters: Comparison in serum and plasma samples
11. Results of transrectal ultrasound-guided biopsies and clinical significance of Japanese prostate cancer
12. Comparative analysis of complexed PSA, free PSA and their ratio in detecting prostate cancer
13. Measurement of complexed PSA improves specificity for early detection of prostate cancer
14. Complexed prostate-specific antigen and its volume indexes in the detection of prostate cancer
15. Prostate specific antigen adjusted for transition zone volume. The most powerful method for detecting prostate carcinoma
16. Examination of the 3 molecular forms of serum prostate specific antigen for distinguishing negative from positive biopsy: Relationship to transition zone volume
17. Performance of a neural network in detecting prostate cancer in the prostate-specific antigen reflex range of 2.5 to 4.0 ng/ml